Cyrano Therapeutics reports successful Phase 2 trial of CYR-064 for smell loss, advancing to Phase 3 in 2H 20206.Unusual Whales·Feb 17 at 01:36 PMFBT+0.12%XBI-0.60%
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial ResultsGlobeNewswire·Oct 29, 2025 at 09:07 PMCYTH0.00%
Rafael Holdings reports Q3 financials; Cyclo Therapeutics' Phase 3 trial for Niemann-Pick Disease fully enrolled, results due this month.Unusual Whales·Jun 11, 2025 at 11:22 AMCYTH0.00%
Rafael Holdings prioritizes Trappsol Cyclo development, CEO stepping down. TransportNPC Phase 3 trial fully enrolled, results in mid-2025.Unusual Whales·Apr 24, 2025 at 08:37 PMCYTH0.00%
Rafael Holdings merges with Cyclo Therapeutics; Phase 3 trial for Niemann-Pick disease fully enrolled, results due mid-2025.Unusual Whales·Mar 26, 2025 at 11:07 AMCYTH0.00%
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals | RFL Stock NewsStockTitan·Mar 26, 2025 at 10:50 AMCYTH0.00%RFL-1.59%
Rafael Holdings reports Q2 fiscal 2025 results; merger with Cyclo Therapeutics set to close in Q3 pending approvals.Unusual Whales·Mar 13, 2025 at 10:12 PMCYTH0.00%
The Micro-Cap Conundrum: Unveiling Hidden Gems That Could Define the FutureReportErosdelsur·Mar 7, 2025 at 10:26 AMCYTH0.00%
12:02 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholdersprnewswire·Feb 21, 2025 at 05:03 PMCYTH0.00%CARA0.00%
